AOD-9604 vs CJC-1295 + Ipamorelin
AOD-9604 and CJC-1295 + Ipamorelin are studied in overlapping research areas, which is why they are frequently compared. This is a neutral side-by-side reference drawn from published preclinical literature and laboratory handling data.
How they actually differ
Comparing the two: AOD-9604 is 16-residue hgh c-terminal fragment analogue with one intramolecular disulfide, while CJC-1295 + Ipamorelin is combination — ghrh(1-29) analogue plus selective ghrelin-receptor agonist — different molecular classes with different handling consequences; their leading degradation routes differ (disulfide exchange (scrambling) and formation of disulfide-linked dimers, accelerated above about ph 8. for AOD-9604, independent degradation of the two components at different rates, which is the defining stability characteristic of any blend. for CJC-1295 + Ipamorelin), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.
AOD-9604 — origin
AOD-9604 is residues 177-191 of human growth hormone with an extra tyrosine added at the N-terminus (Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe), closed by a disulfide between the two cysteines. It came out of Frank Ng's group at Monash University in Australia and was developed by Metabolic Pharmaceuticals in Melbourne as an obesity candidate. That programme was discontinued in 2007 after a 24-week phase 2b trial did not show a clinically meaningful outcome, and the compound never reached approval as a medicine.
CJC-1295 + Ipamorelin — origin
This is a two-compound blend studied for complementary mechanisms rather than a single molecule. CJC-1295 is a modified GHRH(1-29) fragment with four amino-acid substitutions that resist enzymatic degradation. Ipamorelin is a pentapeptide ghrelin-receptor agonist notable for its selectivity — it was specifically developed to stimulate GH release without the cortisol and prolactin effects of earlier secretagogues like GHRP-6.
AOD-9604 research themes
Heffernan et al. (Endocrinology 2001) compared hGH and AOD9604 over 14 days in obese mice and in β3-adrenergic-receptor knockout mice. Both raised the repressed β3-AR expression in obese mice, but neither changed body weight or lipolysis in the knockout mice over the long-term protocol, leading the authors to conclude the lipolytic actions were not mediated directly through β3-AR.
Ng et al. (Horm Res 2000) studied oral administration of AOD9604 in obese Zucker rats, reporting reduced body-weight gain and increased adipose lipolytic activity, and — unlike intact hGH — no impairment of insulin sensitivity on euglycaemic clamp.
Stier et al. (J Endocrinol Metab 2013) pooled six randomised, double-blind, placebo-controlled trials and reported no change in serum IGF-1, no adverse effect on carbohydrate metabolism, and no anti-AOD9604 antibodies in tested participants. The same development programme did not show a clinically meaningful weight outcome.
Kwon and Park (Ann Clin Lab Sci 2015) gave intra-articular AOD9604, with or without hyaluronic acid, in a collagenase-induced knee osteoarthritis model in rabbits and scored cartilage morphology, histology and lameness.
CJC-1295 + Ipamorelin research themes
GHRH-receptor and ghrelin-receptor agonism act through different mechanisms, which is the rationale for pairing them.
Developed specifically for GH release with minimal cortisol and prolactin effects — its defining pharmacological feature.
Studied for effects on the pattern of GH secretion rather than continuous elevation.
A common endpoint in the preclinical literature for GH-axis compounds.
AOD-9604 handling
- Let the vial reach room temperature before opening.
- Add diluent gently down the vial wall and swirl; do not vortex.
- Keep reducing agents (DTT, TCEP, β-mercaptoethanol) and alkaline buffers away from the stock.
- Label aliquots with reconstitution date and diluent.
CJC-1295 + Ipamorelin handling
- Confirm whether the labelled mass is total blend mass or per-component before calculating concentration.
- Reconstitute the full vial rather than attempting to subdivide dry material — the two components will not partition evenly in powder form.
- Protect from light and refrigerate.
Both third-party tested
Every Popular Peptides batch of AOD-9604 and CJC-1295 + Ipamorelin is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.
AOD-9604 reference
Related comparisons
AOD-9604 and CJC-1295 + Ipamorelin are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.